Project Grant R03CA299053
Award Date 8/7/25
Completion Date 7/31/27
Dollars Obligated $174K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Buffalo, NY 14263, USA
Similar Awards
- The National Cancer Institute awarded Emory University a $1,295,039 Project Grant under the Cancer Treatment Research federal grant program (CFDA 93.395) to conduct research on improving immune modulation for smoldering myeloma, a precursor state to multiple myeloma. The project aims to evaluate how properties of immune cells in smoldering myeloma correlate with progression to clinical myeloma, examine changes in immune cells during therapy with Iberdomide or Iberdomide plus Dexamethasone, and...
- This federal Project Grant award of $100,760 from the National Cancer Institute's (NCI) Cancer Research Manpower program (CFDA 93.398) supports research conducted by the Sloan-Kettering Institute for Cancer Research in New York City. The project aims to engineer biomaterials that can modulate the tumor immune microenvironment, with a focus on developing an innovative RNA interference (RNAi) therapy to inhibit the cancer-promoting factors cyclophilin A and E-selectin in multiple myeloma....
- This federal Project Grant award of $620,521, provided by the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research), supports an integrated mathematical modeling approach to define how the aging bone ecosystem drives multiple myeloma evolution and treatment response. The key products and services to be delivered under this 5-year award, which commenced on January 1, 2025, include: Developing a novel hybrid cellular automata mathematical model to describe the...
- The National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) awarded a $452,540 Project Grant to the Sloan-Kettering Institute for Cancer Research to develop novel T-cell imaging techniques to better understand therapy resistance and treatment efficacy of bispecific T-cell engager (BiTE) antibodies targeting B-cell maturation antigen (BCMA) and G protein coupled receptor class C group 5 member D (GPRC5D) in relapsed and refractory multiple myeloma patients. The...
- This federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $621,156 to The Trustees of the University of Pennsylvania to conduct research aimed at identifying novel regulators of endoplasmic reticulum (ER) homeostasis in malignant plasma cells, with the goal of developing new therapies to target and kill multiple myeloma cells. The 5-year project, starting on January 1, 2025, will leverage experimental systems including a...
- This federal Project Grant award from the National Cancer Institute (CFDA 93.395 Cancer Treatment Research) provides $499,902 to Rowan University to develop a novel MCL-1 inhibitor, KS18, and investigate its potential to reverse chemotherapeutic resistance in multiple myeloma (MM). The key objectives are to: 1) determine if MCL-1 inhibition via KS18 can reverse acquired resistance to standard MM treatments like bortezomib in vitro, 2) evaluate if KS18 can overcome bortezomib resistance in MM...
- This federal Project Grant award, funded by the National Cancer Institute under the Cancer Biology Research program (CFDA 93.396), supports research focused on understanding the relationship between inflammatory signaling in the leptomeninges and the growth of leptomeningeal metastatic tumors. The $730,398 award to the Sloan-Kettering Institute for Cancer Research, located in New York, will leverage mouse models and single-cell RNA sequencing to investigate how cancer cell signals induce...
- This $640,135 federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) supports research to develop a new generation of potent menin inhibitors that can overcome resistance observed in current menin inhibitor treatments for acute myeloid leukemia (AML) patients. The award recipient, the Regents of the University of Michigan, will leverage its expertise in medicinal chemistry and cancer biology to design and test these next-generation menin...
- This federal Project Grant award from the National Cancer Institute (CFDA 93.395 Cancer Treatment Research) provides $198,103 to New York University School of Medicine to investigate the role of the immune microenvironment in melanoma bone metastasis. The research aims to define the mechanisms by which melanoma cells colonize the skeletal system and modify the bone microenvironment, as well as explore the interplay between tumor, skeletal, and immune cells during melanoma bone metastasis. The...
- This $495,715 Project Grant awarded by the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) supports research by the Sloan-Kettering Institute for Cancer Research to decipher the pathogenesis and therapeutic vulnerabilities of acute myeloid leukemia (AML) driven by germline RUNX1 mutations. The project aims to develop faithful preclinical models, including genetically engineered mouse models and patient-derived xenografts, to study the genetic events and disease progression from...